What is the effect of olaparib (olaparib, Lipadro) combined with temozolomide?

The therapeutic effect of olaparib (Olaparib, also known as Lipadro) combined with temozolomide has shown a certain efficacy based on the results of multiple clinical trials.

A total of 50 subjects received the combination of olaparib and temozolomide in a clinical trial that included Phase I and Phase II clinical trials. These patients were all patients with small cell lung cancer who had received at least one prior treatment and had relapsed. The trial results showed that the patient's objective response rate reached 41.7%. This means that nearly half of the patients had their tumors shrink or disappear after receiving the combination treatment, which is a very significant treatment effect.

In addition to objective response rates, the combination regimen also demonstrated good disease control rates. In the above-mentioned clinical trials, the overall disease control rate reached 79.2%. This means that the condition of most patients has been effectively controlled without further deterioration.

For patients who received the combination of olaparib and temozolomide, the median progression-free survival was 4.2 months and the median overall survival was 8.5 months. These data suggest that combination treatment regimens can extend patients' survival and provide them with more treatment options and chances of survival.

Although temozolomide may cause some side effects, such as nausea, vomiting, fatigue, etc., these are controllable. Doctors will adjust the treatment plan based on the patient's response to ensure the safety and effectiveness of the treatment. At the same time, both olaparib and temozolomide have generic versions available on the market, which reduces the cost of treatment and makes this combination treatment affordable for more patients.